01:41:35 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

2025-01-28 Bokslutskommuniké 2024
2024-10-24 Kvartalsrapport 2024-Q3
2024-07-12 Kvartalsrapport 2024-Q2
2024-04-26 Ordinarie utdelning XVIVO 0.00 SEK
2024-04-25 Årsstämma 2024
2024-04-24 Kvartalsrapport 2024-Q1
2024-01-25 Bokslutskommuniké 2023
2023-10-24 Kvartalsrapport 2023-Q3
2023-07-13 Kvartalsrapport 2023-Q2
2023-04-26 Ordinarie utdelning XVIVO 0.00 SEK
2023-04-25 Årsstämma 2023
2023-04-24 Kvartalsrapport 2023-Q1
2023-01-26 Bokslutskommuniké 2022
2022-10-27 Kvartalsrapport 2022-Q3
2022-07-13 Kvartalsrapport 2022-Q2
2022-04-27 Ordinarie utdelning XVIVO 0.00 SEK
2022-04-26 Årsstämma 2022
2022-04-25 Kvartalsrapport 2022-Q1
2022-01-27 Bokslutskommuniké 2021
2021-10-28 Kvartalsrapport 2021-Q3
2021-07-13 Kvartalsrapport 2021-Q2
2021-04-23 Ordinarie utdelning XVIVO 0.00 SEK
2021-04-22 Årsstämma 2021
2021-04-21 Kvartalsrapport 2021-Q1
2021-01-28 Bokslutskommuniké 2020
2020-10-23 Kvartalsrapport 2020-Q3
2020-10-14 Extra Bolagsstämma 2020
2020-07-10 Kvartalsrapport 2020-Q2
2020-04-09 Kvartalsrapport 2020-Q1
2020-04-01 Ordinarie utdelning XVIVO 0.00 SEK
2020-03-31 Årsstämma 2020
2020-01-30 Bokslutskommuniké 2019
2019-10-24 Kvartalsrapport 2019-Q3
2019-07-12 Kvartalsrapport 2019-Q2
2019-04-26 Ordinarie utdelning XVIVO 0.00 SEK
2019-04-25 Årsstämma 2019
2019-04-24 Kvartalsrapport 2019-Q1
2019-02-08 Bokslutskommuniké 2018
2018-10-26 Kvartalsrapport 2018-Q3
2018-07-13 Kvartalsrapport 2018-Q2
2018-04-30 Ordinarie utdelning XVIVO 0.00 SEK
2018-04-27 Årsstämma 2018
2018-04-26 Kvartalsrapport 2018-Q1
2018-02-09 Bokslutskommuniké 2017
2017-10-27 Kvartalsrapport 2017-Q3
2017-07-14 Kvartalsrapport 2017-Q2
2017-04-27 Ordinarie utdelning XVIVO 0.00 SEK
2017-04-26 Årsstämma 2017
2017-04-25 Kvartalsrapport 2017-Q1
2017-04-10 Extra Bolagsstämma 2017
2017-02-08 Bokslutskommuniké 2016
2016-10-27 Kvartalsrapport 2016-Q3
2016-07-15 Kvartalsrapport 2016-Q2
2016-05-04 Ordinarie utdelning XVIVO 0.00 SEK
2016-05-03 Årsstämma 2016
2016-04-26 Kvartalsrapport 2016-Q1
2016-02-04 Bokslutskommuniké 2015
2015-10-23 Kvartalsrapport 2015-Q3
2015-08-13 Kvartalsrapport 2015-Q2
2015-04-24 Ordinarie utdelning XVIVO 0.00 SEK
2015-04-23 Årsstämma 2015
2015-04-22 Kvartalsrapport 2015-Q1
2015-02-05 Bokslutskommuniké 2014
2014-10-24 Kvartalsrapport 2014-Q3
2014-10-24 Analytiker möte 2014
2014-08-13 Kvartalsrapport 2014-Q2
2014-04-30 Ordinarie utdelning XVIVO 0.00 SEK
2014-04-29 Årsstämma 2014
2014-04-23 Kvartalsrapport 2014-Q1
2014-02-07 Bokslutskommuniké 2013
2013-11-07 Analytiker möte 2013
2013-11-07 Kvartalsrapport 2013-Q3
2013-07-11 Kvartalsrapport 2013-Q2
2013-05-08 Ordinarie utdelning XVIVO 0.00 SEK
2013-05-07 Årsstämma 2013
2013-04-19 Kvartalsrapport 2013-Q1
2013-02-19 Bokslutskommuniké 2012
2012-11-01 Kvartalsrapport 2012-Q3

Beskrivning

LandSverige
ListaMid Cap Stockholm
SektorHälsovård
IndustriMedicinteknik
Xvivo Perfusion är verksamt inom medicinteknik. Bolaget tillhandahåller lösningar för transplantation av lungor. Exempel på produkter som bolaget levererar innefattar kanyler, organförvaring samt kyllösningar. Produkterna vidaresäljs till kliniker och forskningsinstitut runtom den globala marknaden, med störst närvaro inom Norden och Europa. Bolaget kom till via en avknoppning från Vitrolife under 2012 och har sitt huvudkontor i Göteborg.
2023-10-23 20:15:00

On October 14, 2023 Duke University Hospital in Durham, N.C., performed the first heart transplant in the U.S. using XVIVO’s Non-Ischemic Heart Preservation (NIHP) device and solution as part of the PRESERVE clinical trial: A Prospective, Multi-center, Single-Arm, Open-Label Study of Hearts Transplanted after Non-Ischemic Heart PRESERVation from Extended Donors.

The PRESERVE multicenter clinical trial is designed to evaluate the safety and effectiveness of the XVIVO heart technology that will be used in support of a Pre-Market Approval (PMA) with the FDA. The trial will enroll 141 patients across 20 leading transplant centers in the USA. Amongst other inclusion criteria, the trial will allow transplant centers to include extended criteria donor hearts such as hearts from older donors (defined as aged 50 years old or above), from long-distance donors, and hearts from donation after circulatory death (DCD) donors.

“We are delighted that the team at Duke University Hospital successfully performed the first heart transplant using this novel technology in North America as part of our clinical trial. They performed more heart transplants than any other center worldwide in 2022[1] and are a center of research excellence. We are eager to support Duke’s efforts and look forward to initiating more heart transplant centers nationwide into the trial to support their mission of providing more patients with life-saving transplantations,” says Jaya Tiwari, VP Clinical & Regulatory Affairs USA, XVIVO.

“First and foremost, I would like to extend my congratulations to Duke University Hospital's transplant team for the successful transplantation. The initiation of the U.S. PRESERVE trial marks the fourth clinical trial utilizing our innovative heart technology. We also anticipate the forthcoming publication of promising results from an investor-initiated clinical trial in Australia and New Zealand. The technology is currently being utilized in approximately 30 percent of all heart transplants in that region under special compassionate use permission (i.e. before regulatory approval).

In May, our European randomized controlled clinical trial across 15 leading transplant centers in 8 European countries completed its patient recruitment. Simultaneously, there is an ongoing clinical trial in Lund, Sweden. We firmly believe that XVIVO's groundbreaking heart technology has the potential to change the paradigm in heart preservation, as it will open up for using more available hearts and, consequently, saving more lives,” says Christoffer Rosenblad, CEO XVIVO.

Gothenburg
October 23, 2023
Christoffer Rosenblad, CEO
XVIVO Perfusion AB (publ)


[1] https://optn.transplant.hrsa.gov/data/view-data-reports/national-data/